18 drug national suspensions involving 14 pharmaceutical companies (attached list)

18 drugs, the national suspension of supply, mainly based on the drug and low-cost drugs.
1, 18 drugs, the national suspension of supply recently, Shanxi Province drug equipment centralized bidding procurement network issued two consecutive "on the publicity of some pharmaceutical production enterprises to apply for revocation of the direct hanging network product platform registration network qualification notice."
According to Seber blue combing, the two notifications involved a total of 18 pharmaceutical regulations of 14 pharmaceutical companies, including thrombosis capsules, injection of simitide, injection of sodium sodium sulphate with hydrogenated cocoa, injection of cephalosporine (sodium carbonate), injection of cephalosporine Sodium citrine, bear deoxycholic acid tablets, injection nieme cornelin, antiviral capsules, kidney corning tablets,acid alvelin, injection with sodium aweisate, chrysanthemum on the pill, sodium heparin injection, strong liver capsules, children's lung fever cough wheezing particles and so on.
the withdrawal of the above-mentioned drugs, Seber blue consulted the corresponding pharmaceutical companies, but for the time being did not get a clear statement.
it is worth noting that some of the 18 varieties in which the enterprise applied for the removal of the net published the winning bid price - the lowest price is cephalosporine for injection (sodium carbonate), 0.5g x 1 specification price is 1. 27 yuan, the lower price is 0.2g x 1 specification of injection simitide, the highest price is 50mg x 30 size of bear deoxycholic acid tablets, the winning bid price of 54.8.
, the varieties that have applied for removal are based on essential drugs, low-cost drugs, and non-base drugs that have historically purchased a small amount.
shi Lichen, founder of Beijing Dingchen Pharmaceutical Management Consulting Center, said that the phenomenon of API monopoly is now more common, all kinds of costs rise, the original tender price has been difficult to cover costs, for enterprises, supply may mean losses, enterprises can only choose to take the initiative to withdraw the network.
is also noteworthy, and related to this is for low-cost drugs and base drug catalog, business participation enthusiasm is decreasing.
notice said that in accordance with shanxi Province in 2015 public medical institutions centralized classification of drug procurement regulations, Zhengda Youth Bao Pharmaceutical Co., Ltd. and other pharmaceutical companies to apply to revoke the relevant direct hanging network product platform registration qualification, at the same time, the enterprise also provided a unified national commitment not to supply.
that is to say, in addition to the above-mentioned drugs in Shanxi Province no longer supply public hospital market, across the country, the above-mentioned drugs have also given up in the provinces to recruit platforms to hang up the qualifications, basically equivalent to giving up the national policy of the internal market.
on the recruitment platform requires pharmaceutical companies to submit a unified national commitment not to supply, Slichen said to Cypress Blue, as the provinces to promote the sun tender procurement, pharmaceutical companies nationwide online prices gradually converge, the gap will not be very large, pharmaceutical companies in this province prices can not cover costs, the gap in other provinces will not be very large, so there is no substantive impact on enterprises.
On the follow-up sale of these drugs, Mr. Slichen pointed out to Seberan that there are also out-of-policy markets such as retail pharmacies, private chains, and private hospitals, where price pressures on companies may be relatively easy.
it's worth noting that the share of these terminals is much smaller than in the public hospital market.
And take this application to withdraw the network of these drugs, nine of them are injection forms, as the main dosage form used in public hospitals, for public hospitals more terminal dependence, once unable to supply the public hospital market, the impact may be inevitable.
2, a variety of factors lead to enterprises to withdraw the network to stop supply it is worth noting that pharmaceutical companies actively apply for the withdrawal of the phenomenon is not uncommon.
According to combing, this year, Shanxi Province alone has issued a number of enterprises to apply for the withdrawal of the network notice - according to the notice in May, Zhejiang Yongning Pharmaceuticals and other 15 pharmaceutical companies 66 drug regulations to withdraw the direct network products of the online qualification;
On January 8, 2020, Hainan Province Pharmaceutical Centralized Purchasing Center issued the Notice on the Publicity of Part of the Drug Withdrawal Network, according to a total of 250 drug applications to cancel the network - of which 171 drug applications for removal of the network is due to rising production costs, can not be normal supply, production line transformation, production line stop and other reasons lead to production stoppages;
On January 22, 2020, Ningxia Pharmaceutical Centralized Procurement Network issued a notice that it would disqualified 48 standard drugs, such as Edostein capsules, from winning the bid (hanging net) - of which 46 applied for revocation of the net and 2 applied for scrapping the target.
In addition to the common cost increases, raw material prices, production line transformation and other reasons caused by drug companies to withdraw the network, it is worth noting that in Shanxi to apply for the withdrawal of the network of varieties, one is the previous Shanxi Province to carry out injection belt procurement of one of the 21 varieties, that is, injection cephalosporine sodium.
, according to the latest data from Mi Intranet, the end-user sales of cephalosporine for injection in China's public medical institutions reached 4.48 billion yuan in 2019, ranking among the top 20 pharmaceutical sales in China.
Due to the mature clinical use, large procurement amount, relatively full competition, many production enterprises, injection cephalosporine was selected as a local collection of varieties in Shanxi Province, and in the qualification audit stage, this variety alone through Shanxi injection collection qualification audit of the number of enterprises there are 23.
In accordance with the relevant provisions of Shanxi Province collection documents, the procurement alliance medical institutions in the 2019 selected products of the generic drug Shanxi Province pharmaceutical procurement platform procurement volume of 70% as the agreed procurement volume, that is, the selected injection of cephalosporine Rosin Pharmaceuticals obtained 70% of the total procurement volume.
From the situation of this heavy variety can be seen, in addition to the national organization of drug collection and normal promotion, in the country's multi-province provincial collection and inter-provincial alliance collection, but also for clinically commonly used varieties of a round of market reshuffle, once the chinese drug companies get more than 50 percent of the public hospital market, the market share of other unelested varieties will be greatly compressed, which may also become one of the driving factors for the subsequent withdrawal of the network.
On the withdrawal of low-cost drugs, stop supply issues, there are industry insiders said that the current policy, such as volume procurement, more attention in the price compression space of varieties, and low-cost drugs to some extent lack of corresponding attention.
For some time now, these low-cost drugs, due to the low provincial bid price, in the clinical promotion link there is no market space, difficult to compete with the higher market space varieties, the willingness of doctors to prescribe is low, and not like the national collection of selected varieties as guaranteed use of measures, sales in public hospital terminals are not high, once the cost rises again, enterprises will naturally be difficult to afford.
: the original title of the catalogue of drug product regulations to be revoked: 18 drugs nationwide suspension of supply (attached list)